Log in
NASDAQ:NGM

NGM Biopharmaceuticals Stock Forecast, Price & News

$17.05
+0.05 (+0.29 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$16.88
Now: $17.05
$17.34
50-Day Range N/A
52-Week Range
$9.24
Now: $17.05
$23.95
Volume60,382 shs
Average Volume143,071 shs
Market Capitalization$1.17 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.76
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.90 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NGM
CUSIPN/A
CIKN/A
Phone650 243 5555
Employees186

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$103.54 million
Book Value$4.96 per share

Profitability

Net Income$-42,790,000.00

Miscellaneous

Market Cap$1.17 billion
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$17.05
+0.05 (+0.29 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NGM News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











NGM Biopharmaceuticals (NASDAQ:NGM) Frequently Asked Questions

When is NGM Biopharmaceuticals' next earnings date?

NGM Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for NGM Biopharmaceuticals
.

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) issued its earnings results on Wednesday, August, 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.05. The business earned $19.76 million during the quarter, compared to analyst estimates of $20.42 million. NGM Biopharmaceuticals had a negative net margin of 73.98% and a negative return on equity of 22.20%.
View NGM Biopharmaceuticals' earnings history
.

Who are some of NGM Biopharmaceuticals' key competitors?

Who are NGM Biopharmaceuticals' key executives?

NGM Biopharmaceuticals' management team includes the following people:
  • Mr. William J. Rieflin J.D., Exec. Chairman of Directors (Age 60)
  • Dr. David J. Woodhouse, CEO & Director (Age 49, Pay $615.75k)
  • Dr. Jin-Long Chen, Founder, Chief Scientific Officer & Director (Age 57, Pay $625.75k)
  • Dr. Aetna Wun Trombley, Consultant (Age 40, Pay $550.75k)
  • Ms. Siobhan Nolan Mangini, CFO and Principal Financial & Accounting Officer (Age 39)

When did NGM Biopharmaceuticals IPO?

(NGM) raised $100 million in an IPO on Thursday, April 4th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen acted as the underwriters for the IPO.

What is NGM Biopharmaceuticals' stock symbol?

NGM Biopharmaceuticals trades on the NASDAQ under the ticker symbol "NGM."

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NGM Biopharmaceuticals' stock price today?

One share of NGM stock can currently be purchased for approximately $17.05.

How big of a company is NGM Biopharmaceuticals?

NGM Biopharmaceuticals has a market capitalization of $1.17 billion and generates $103.54 million in revenue each year. The company earns $-42,790,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. NGM Biopharmaceuticals employs 186 workers across the globe.

What is NGM Biopharmaceuticals' official website?

The official website for NGM Biopharmaceuticals is www.ngmbio.com.

How can I contact NGM Biopharmaceuticals?

NGM Biopharmaceuticals' mailing address is 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650 243 5555 or via email at [email protected]

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.